Literature DB >> 30915738

MicroRNA-101-5p inhibits the growth and metastasis of cervical cancer cell by inhibiting CXCL6.

W Shen1, X-Y Xie, M-R Liu, L-L Wang.   

Abstract

OBJECTIVE: The objective of this study is to explore the biological roles of microRNA-101-5p (miR-101-5p) in the growth and metastasis of cervical cancer. PATIENTS AND METHODS: The levels of miR-101-5p and chemokine (C-X-C motif) ligand 6 (CXCL6) in cervical cancer tissues and cells were detected using the quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) assay. The proliferation, colony formation, migration, and invasion assays were conducted using miR-101-5p transfected cervical cancer cell. The expression of CXCL6 was measured by the immunoblotting assay. Xenograft model was constructed to reveal the precise roles of miR-101-5p in the growth of cervical cancer cell in vivo.
RESULTS: MiR-101-5p was down-regulated in cervical cancer tissues when compared to the normal controls. The levels of miR-101-5p were higher in cervical cancer cells (SiHa, Caski, C-4-I, C-33 A) than that in the human cervical surface epithelial cell line, HcerEpic. Over-regulation of miR-101-5p inhibited the aggressiveness phenotypes of a cervical cancer cell in vitro. Furthermore, over-regulation of miR-101-5p reduced the tumor growth of cervical cancer cell in vivo. CXCL6 was the target protein of miR-101-5p in cervical cancer as demonstrated by luciferase reporter assay. The mRNA level of CXCL6 was negatively associated with the miR-101-5p level in cervical cancer tissue. Finally, the rescue experiments suggested that the inhibitory role of miR-101-5p was mediated by regulating the expression of CXCL6 in cervical cancer.
CONCLUSIONS: These findings indicated that the over-regulation of miR-101-5p suppressed the progression of cervical cancer by targeting CXCL6 and might function as a potential therapeutic target for cervical cancer.

Entities:  

Year:  2019        PMID: 30915738     DOI: 10.26355/eurrev_201903_17234

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA.

Authors:  Tandrima Mitra; Selvakumar Elangovan
Journal:  Mol Cell Biochem       Date:  2021-08-28       Impact factor: 3.396

2.  Characterization of the Prognostic Values of CXCL Family in Epstein-Barr Virus Associated Gastric Cancer.

Authors:  Li Mu; Shun Hu; Guoping Li; Ping Wu; Caihong Ren; Taiyu Lin; Sheng Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-06-01       Impact factor: 7.310

3.  Circular RNA hsa_circ_0007364 increases cervical cancer progression through activating methionine adenosyltransferase II alpha (MAT2A) expression by restraining microRNA-101-5p.

Authors:  Hongfei Chen; Bin Gu; Xiang Zhao; Yupeng Zhao; Shuning Huo; Xiang Liu; Huihong Lu
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

4.  miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.

Authors:  Lisa Svartdal Normann; Mads Haugland Haugen; Miriam Ragle Aure; Vessela N Kristensen; Gunhild Mari Mælandsmo; Kristine Kleivi Sahlberg
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-03-01

Review 5.  Emerging Roles and Potential Applications of Non-Coding RNAs in Cervical Cancer.

Authors:  Deepak Parashar; Anupam Singh; Saurabh Gupta; Aishwarya Sharma; Manish K Sharma; Kuldeep K Roy; Subhash C Chauhan; Vivek K Kashyap
Journal:  Genes (Basel)       Date:  2022-07-15       Impact factor: 4.141

Review 6.  Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.

Authors:  Aysegul Dalmizrak; Ozlem Dalmizrak
Journal:  Front Bioeng Biotechnol       Date:  2022-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.